GENEVA: The Atherosclerosis Risk in Communities (ARIC) Study

This sub-study phs000090 GENEVA ARIC contains genotype data and selected phenotype of subjects available from the phs000090 study. Summary level phenotypes for the NHLBI ARIC Cohort study participants can be viewed at the top-level study page phs000280 ARIC Cohort. Individual level phenotype data and molecular data for all ARIC Cohort top-level study and sub-study are available by requesting Authorized Access to the NHLBI ARIC Cohort phs000280 study.

The Atherosclerosis Risk in Communities (ARIC) Study, sponsored by the National Heart, Lung and Blood Institute (NHLBI), is a prospective epidemiologic study conducted in four U.S. communities. The four communities are Forsyth County, NC; Jackson, MS; the northwest suburbs of Minneapolis, MN; and Washington County, MD. ARIC is designed to investigate the etiology and natural history of atherosclerosis, the etiology of clinical atherosclerotic diseases, and variation in cardiovascular risk factors, medical care and disease by race, gender, location, and date.

ARIC includes two parts: the Cohort Component and the Community Surveillance Component. The Cohort Component began in 1987, and each ARIC field center randomly selected and recruited a cohort sample of approximately 4,000 individuals aged 45-64 from a defined population in their community. A total of 15,792 participants received an extensive examination, including medical, social, and demographic data. These participants were reexamined every three years with the first screen (baseline) occurring in 1987-89, the second in 1990-92, the third in 1993-95, and the fourth and last exam was in 1996-98. Follow-up occurs yearly by telephone to maintain contact with participants and to assess health status of the cohort.

In the Community Surveillance Component, currently ongoing, these four communities are investigated to determine the community-wide occurrence of hospitalized myocardial infarction and coronary heart disease deaths in men and women aged 35-84 years. Hospitalized stroke is investigated in cohort participants only. Starting in 2006, the study conducts community surveillance of inpatient (ages 55 years and older) and outpatient heart failure (ages 65 years and older) for heart failure events beginning in 2005.

ARIC is currently funded through January 31, 2012.

This study is part of the Gene Environment Association Studies initiative (GENEVA, http://www.genevastudy.org) funded by the trans-NIH Genes, Environment, and Health Initiative (GEI). The overarching goal is to identify novel genetic factors that contribute to atherosclerosis and cardiovascular disease through large-scale genome-wide association studies of well-characterized cohorts of adults in four defined populations. Genotyping was performed at the Broad Institute of MIT and Harvard, a GENEVA genotyping center. Data cleaning and harmonization were done at the GEI-funded GENEVA Coordinating Center at the University of Washington.

• Study Weblinks:
  • ARIC
• Study Design:
  • Case-Control
• Study Type:
  • Case-Control
• dbGaP estimated ancestry using GRAF-pop
• Total number of consented subjects: 12771
• Subject Sample Telemetry Report (SSTR)

• PubMed

Aged 45-64 at baseline

The cohort was examined at 4 clinic visits:
Visit 1: 1987-89
Visit 2: 1990-92
Visit 3: 1993-95
Visit 4: 1996-98

• Primary Phenotype: Cardiovascular Diseases
• Atherosclerosis
• Cardiovascular System
• Stroke
• Cholesterol
• Diabetes Mellitus
• Heart Diseases
• Heart Failure, Congestive
• Hypertension
• Myocardial Infarction
• Obesity
• Risk Factors
• Smoking

• Principal Investigators (Field Center)
  • Aaron R. Folsom, MD. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
  • Gerardo Heiss, MD. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Thomas H. Mosley Jr., PhD. Department of Medicine (Geriatrics), University of Mississippi Medical Center, Jackson, MS, USA.
  • Josef Coresh, MD, PhD. Department of Epidemiology, Biostatistics, and Medicine, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
• Principal Investigator (Atherosclerosis Clinical Research Laboratory)
  • Christie M. Ballantyne, MD. Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
• Principal Investigator (Central DNA Laboratory)
  • Eric Boerwinkle, PhD. Human Genetics Center, University of Texas School of Public Health, Houston, TX, USA.
• Principal Investigator (Coordinating Center)
  • Lloyd E. Chambless, PhD. Collaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
• Project Officer
  • Jacqueline Wright, DrPH. National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.